Conference abstract · 15 Oct 2013
Conference abstractPublished 20 Nov 2013
Engineering cells and tissues with exogenous immunomodulatory proteins for the induction of tolerance to auto and alloantigens
University of Louisville, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Type 1 diabetes (T1D) is a chronic autoimmune disease that targets the destruction of insulin-producing beta cells, leading to insulin deficiency and hyperglycemia. Exogenous insulin treatment is the standard of care for type 1 diabetic patients. However, daily insulin treatment not only negatively affect the quality of life, but is also often ineffective in preventing recurrent hyperglycemic episodes with consequent development of microand macroangiopathic lesions and the development and progression of chronic complications. Allogeneic islet transplantation has proven effective in improving metabolic control/quality of life and in preventing severe hypoglycemia in patients with T1D. However, broad application of clinical allogeneic islet transplantation is limited by immune rejection despite the chronic use of immunosuppression and its sequelae. Therefore, novel approaches that control rejection in the absence of chronic immunosuppression will have significant impact on the field of islet transplantation. Allogeneic islet rejection in diabetic individuals are primarily initiated and perpetuated by recipient T cells. Control of T cell responses has the potential to induce tolerance and treatment of T1D. T cells upregulate Fas receptor and become sensitive to Fas/FasL-mediated killing. Therefore, we have recently developed a novel form of FasL protein and displayed it on the surface of pancreatic islets in a rapid and efficient manner without any detrimental effect on the function of islets. Transplantation of FasL-engineered islets into allogeneic diabetic recipients resulted in tolerance and treatment of diabetes. Apoptosis of pathogenic T cells followed by a circuit of regulatory mechanisms were responsible for the induced tolerance. Therefore, the direct display of immunological ligands on the surface of islets serves as a rapid, efficient, and clinically applicable approach for immunomodulation with implications in clinical islet transplantation.
Subjects
BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 19 Mar 2018
Engineering bone marrow cells with an immunomodulatory protein for the prevention of graft-vshost disease
Conference abstract · 19 Mar 2018
Induction of tolerance to allogeneic islet grafts using an immunomodulatory biomaterial
Conference abstract · 25 Mar 2019
PLG scaffolds engineered with an immunomodulatory molecule as an effective means of establishing localized tolerance to pancreatic islet grafts
Conference abstract · 12 Nov 2012
Auto-inductive scaffolds: Orthogonal grafting of different peptides to scaffolds for concurrent differentiation of cells to multiple lineages
More from this journal
The newest in Journal of Cell Science & Therapy.
Perspective · 2 Feb 2026
Exploring Senescence and Its Influence on Tissue Function and Therapeutic Research
Commentary · 2 Feb 2026
Metabolism Regulation and Its Influence on Therapeutic Development in Human Disease
Commentary · 2 Dec 2025
Cellular Membranes and Transport Proteins as Regulators of Homeostasis and Metabolic Coordination
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cell Science & Therapy
- SubjectBiology
- BylineArticles whose byline prints “Haval Shirwan”

